Frontiers in Oncology is a broad-scope, multidisciplinary journal covering all areas of cancer research to advance our knowledge of cancer epidemiology to improve diagnosis, therapeutics, and management strategies.

The journal is led by Field Chief Editor Prof Giuseppe Giaccone (Cornell University and Amgen, USA), and Assistant Field Chief Editor Prof Sharon Pine (University of Colorado, USA). Indexed in PubMed Central (PMC), Scopus, Web of Science (SCIE), and the DOAJ, Frontiers in Oncology welcomes clinical and experimental research contributions in the various domains of cancer research, which bridge the gap between basic research and clinical applications. Topics include, but are not limited to:

breast cancer
cancer cell signaling
cancer epidemiology and prevention
cancer genetics
cancer imaging and image-directed interventions
cancer immunity and immunotherapy
cancer metabolism
cancer molecular targets and therapeutics
cardio-oncology
gastrointestinal cancers
genitourinary oncology
gynecological oncology
head and neck cancer
hematologic malignancies
molecular and cellular oncology
neuro-oncology and neurosurgical oncology
pediatric oncology
pharmacology of anti-cancer drugs
radiation oncology
skin cancer
surgical oncology
thoracic oncology.

In particular, the journal welcomes submissions which support and advance the UN’s Sustainable Development Goals (SDGs), notable SDG 3: ensure healthy lives and promote well-being for all at all ages.

Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.

Frontiers in Oncology is committed to advancing developments in the field of cancer research by allowing unrestricted access to articles, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.

Impact

Frontiers in Oncology

Skin Cancer